Clinical Research Directory
Browse clinical research sites, groups, and studies.
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Sponsor: Agenus Inc.
Summary
This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.
Official title: Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-05-06
Healthy Volunteers
Not specified
Conditions
Interventions
Balstilimab
An anti-programmed death 1 (PD-1) monoclonal antibody.
Zalifrelimab
An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
Locations (7)
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Oncology Associates
Tucson, Arizona, United States
Hoag Gynecologic Oncology
Newport Beach, California, United States
University of California, San Francisco Medical Center
San Francisco, California, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
Texas Oncology
Flower Mound, Texas, United States